Session Information
Date: Monday, September 23, 2019
Session Title: Clinical Trials, Pharmacology and Treatment
Session Time: 1:45pm-3:15pm
Location: Agora 3 West, Level 3
Objective: To describe the achievements of the French NS-PARK/FCRIN network (http://www.parkinson.network/) after 5 years of activity.
Background: The French Clinical Research Infrastructure network FCRIN is a national distributed clinical research infrastructure funded by the French government to boost clinical academic and industry-sponsored trials in France (https://www.fcrin.org/). FCRIN labeled and funded in 2013 twelve investigation networks, including NS-PARK which brings together the 25 French Expert Centers for Parkinson’s disease (PD) and movement disorders, with special focus on early interventional trials and large national/international multicenter trials.
Method: Quantitative and qualitative indicators of activity collected according to pre-specified outcomes elaborated by the FCRIN evaluation work-package and audited in 2018 by the FCRIN external international scientific committee.
Results: Within 5 years, NS-PARK developed efficient organization, governance and operational processes, based on an executive board and a steering committee, supported by 3 full-time coordination managers and a sustainable business model. It gathers top scientific and methodological expertise to develop and conduct clinical trials in PD in France, providing a single centralized access to its centers using common recruitment strategies, harmonized costs, standardized quality system, training and access to research facilities. NS-PARK has implemented a national cohort of PD patients (~20 000 patients prospectively followed-up using a common clinical eCRF; see poster by Alfaisal et al) and is currently developing its biobank (see PRECISE-PD poster by Corvol et al) and imaging database. From 2013 to 2018, NS-Park has conducted or contributed to 62 projects, 55% being sponsored and funded by academic entities [European (IMI/H2020) or national (PHRC) grants] and 45% by 32 industrial companies, for a global amount of 30 M€, including more than 2700 PD patients, doubling the rate of inclusion of French centers over the period, and producing 50 international peer-reviewed publications.
Conclusion: NS-PARK/FCRIN was efficient in improving clinical research in PD in France. Further funding is recommended, with the objective for the next 5 years to integrate clinical, biological, imaging and health care data analyses to develop personalized approaches of PD management.
To cite this abstract in AMA style:
O. Rascol, JC. Corvol, F. Durif, E. Delappina, V. Chaigneau, JP. Azulay, P. Couratier, L. Defebvre, D. Devos, P. Damier, A. Doe, S. Drapier, S. Frismand, C. Geny, C. Giordana, JL. Houeto, P. Krystkowiak, E. Magnin, D. Maltete, W. Meissner, T. Moreau, E. Moro, P. Remy, C. Thiriez, S. Thobois, C. Tranchant, F. Viallet, M. Vidailhet. The French NS-PARK/FCRIN network: a 5-year balance sheet [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/the-french-ns-park-fcrin-network-a-5-year-balance-sheet/. Accessed June 14, 2025.« Back to 2019 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/the-french-ns-park-fcrin-network-a-5-year-balance-sheet/